Compare Citius Pharmaceuticals Inc (CTXR) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.06B). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is far larger — about 224.7× Citius Pharmaceuticals Inc's market cap, and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 16 Days on average.
| CTXR | FLRN | |
|---|---|---|
Market Cap | $13.62M | $3.06B |
Volume | 132,438 | 6,296,473 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $30.86 |
52-Week Low | $0.48 | $30.65 |
Typical Hold Time | 17 Days | 16 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.77 with minimal daily movement (+0.07%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent quarterly dividends of $0.11, with recent institutional buying interest from Concurrent Investment Advisors. Current market focus centers on floating rate bonds' performance amid rising interest rate expectations.
FLRN offers exposure to investment-grade floating rate bonds with near-zero duration, positioning it as a potential hedge against rate hikes. Key risks include concentrated financial sector exposure and sensitivity to credit spread changes. The ETF's structure provides income stability but faces headwinds from potential economic slowdowns affecting corporate bond markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →
